Each year, there are an increasing number of biologics and specialty drugs produced for a number of rare and chronic conditions. With more of these drugs coming down the pipeline and faster drug approvals, employers continue to seek effective management strategies that support the health and productivity of their workforce, drive optimal patient outcomes, address transparency issues from third-party program administrators and positively impact the bottom line.
But there are still gaps. Employers recognize that specialty drug management requires different thinkingaround benefit design, yet industry surveys indicate employers have made little to no change in their approaches and identification of best practices.
Proven strategies that can provide a road map to all have also failed to emerge, but promising approaches are on the horizon.
What You’ll Discover After Reading This Report
Packed with industry analysis and expert insights to develop your strategy, it covers:
- a comprehensive overview of the current challenges
- a summary of the key issues plan sponsors must address
- insights into best practices
- how to succeed using an innovative new approach to maximize clinical and economic investments, Medical Benefit Drug Management (MBM)
Report insights presented in collaboration
with NICH founding company Access Market Intelligence